Scholarlink

Purpose <p>To report safety and efficacy (on terms of long-term pain reduction results) after percutaneous splanchnic nerve cryoneurolysis for the treatment of refractory pancreatic cancer-related pain.</p> Materials and Methods <p>This single-center, institutional review board-approved, retrospective observational study recruited consecutive patients with pancreatic cancer-related pain refractory to conservative treatment who underwent CT-guided cryoneurolysis of the splanchnic nerves. Outcomes included overall pain reduction rate (&gt; 4 pain score units in the VAS pain scores), technical success (successful cryoprobe placement at the level of interest), and opioid usage reduction.</p> Results <p>Fifty patients were included (mean age 65 ± 7&#xa0;years). Overall, clinically relevant pain reduction was achieved in 76% of the patients (38/50). Baseline mean self-reported pain score was 9.52 ± 0.6 (range 8–10) reduced to a mean value of 4.36 ± 2.9, 4.23 ± 3, and 4.43 ± 3.1 after 1, 6, and 12&#xa0;months, respectively. Technical success was achieved in 100% (50/50) of the patients. Reduction in opioid analgesia usage was observed in 76% (38/50) of the patients. Median overall survival after treatment was 21&#xa0;months (interquartile range: 6, 36). A statistically significant difference was observed in the self-reported pain scores at 1, 6, and 12&#xa0;months in patients with and without infiltration of the celiac plexus. No grade &gt; 1b complications, according to the modified CIRSE classification system, were reported.</p> Conclusion <p>This retrospective study highlights that percutaneous cryoneurolysis of the splanchnic nerves is effective and offers long-lasting pain palliation in patients with refractory pancreatic cancer-related pain. This effect is more pronounced when the celiac plexus is not infiltrated by the tumor.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Percutaneous Cryoneurolysis of Splanchnic Nerves for Pain Palliation in Patients with Pancreatic Cancer: A Single-Center Experience

  • 期刊论文

  • 发表日期：

    2025年8月5日

查看全文
  • David-Dimitris Chlorogiannis,
  • Ioannis Kotsantis,
  • Panagiota Economopoulou,
  • Anastasios Kyriazoglou,
  • Stavros Spiliopoulos,
  • Nikolaos Kelekis,
  • Dimitris K. Filippiadis

摘要

Purpose

To report safety and efficacy (on terms of long-term pain reduction results) after percutaneous splanchnic nerve cryoneurolysis for the treatment of refractory pancreatic cancer-related pain.

Materials and Methods

This single-center, institutional review board-approved, retrospective observational study recruited consecutive patients with pancreatic cancer-related pain refractory to conservative treatment who underwent CT-guided cryoneurolysis of the splanchnic nerves. Outcomes included overall pain reduction rate (> 4 pain score units in the VAS pain scores), technical success (successful cryoprobe placement at the level of interest), and opioid usage reduction.

Results

Fifty patients were included (mean age 65 ± 7 years). Overall, clinically relevant pain reduction was achieved in 76% of the patients (38/50). Baseline mean self-reported pain score was 9.52 ± 0.6 (range 8–10) reduced to a mean value of 4.36 ± 2.9, 4.23 ± 3, and 4.43 ± 3.1 after 1, 6, and 12 months, respectively. Technical success was achieved in 100% (50/50) of the patients. Reduction in opioid analgesia usage was observed in 76% (38/50) of the patients. Median overall survival after treatment was 21 months (interquartile range: 6, 36). A statistically significant difference was observed in the self-reported pain scores at 1, 6, and 12 months in patients with and without infiltration of the celiac plexus. No grade > 1b complications, according to the modified CIRSE classification system, were reported.

Conclusion

This retrospective study highlights that percutaneous cryoneurolysis of the splanchnic nerves is effective and offers long-lasting pain palliation in patients with refractory pancreatic cancer-related pain. This effect is more pronounced when the celiac plexus is not infiltrated by the tumor.

Graphical Abstract